Clinical guidelines support medication treatment for adults who have attempted lifestyle changes and meet either BMI threshold below. We personalize every treatment plan based on your health history, comorbidities, and goals.
BMI ≥ 30
Obesity — without a weight-related condition required
BMI ≥ 27
Overweight with at least one comorbidity (hypertension, diabetes, sleep apnea, high cholesterol, etc.)
AVAILABLE TREATMENT
FDA-Approved Weight Loss Medications
We prescribe the full spectrum of anti-obesity medications. Your doctor will recommend the best fit based on your health history, insurance, and preferences — including whether you prefer a pill or injection.
New Oral GLP-1 Medications (Pills)
Wegovy Pill
Oral semaglutide 25 mg · Once Daily · Novo Nordisk
New 2026Pill
The first FDA-approved oral GLP-1 for weight loss (approved December 2025). Oral Wegovy contains the same active ingredient as injectable Wegovy — semaglutide — in a once-dail tablet. No refrigeration required; take on an empty stomach with water. Also reduces risk of major cardiovascular events. Starting price ~$149/month.
Foundayo
Orforglipron · Once Daily · Eli Lilly
New Apr 2026Pill
The second FDA-approved oral GLP-1, approved April 1, 2026. Foundayo (orforglipron) is a once-daily pill from Eli Lilly with a key advantage: it can be taken any time of day, with or without food or water. Available starting ~$149/month.
FDA-approved for chronic weight management. Weekly self-injection that reduces appetite and increases satiety. Clinical trials show average weight loss of 15–17% of body weight. Also approved to reduce cardiovascular risk in adults with obesity and established heart disease.
Ozempic
Injectable semaglutide · Weekly injection · Novo Nordisk
Injection
Ozempic (semaglutide) is FDA-approved for type 2 diabetes and cardiovascular risk reduction. It is commonly prescribed off-label for weight loss in patients with diabetes or prediabetes. Same active ingredient as Wegovy, at a lower approved dose.
A dual GLP-1 and GIP receptor agonist — the only medication of its kind. Clinical trials show average weight loss of 20–22%, making it one of the most effective obesity medications available. Also marketed as Mounjaro for type 2 diabetes management.
Saxenda
Liraglutide 3.0 mg · Daily injection · Novo Nordisk
Injection
FDA-approved for weight management in adults and adolescents ≥12. A daily injectable GLP-1 with a longer track record. An option for patients who cannot access or tolerate weekly GLP-1 medications.
Other FDA-Approved Options
Qsymia
Phentermine + Topiramate · Oral · Daily
Pill
Combines an appetite suppressant (phentermine) with a seizure/migraine medication (topiramate) to reduce hunger and promote weight loss.
Contrave
Naltrexone + Bupropion · Oral · Daily
Pill
Acts on brain reward pathways to reduce cravings and emotional eating. Combines a medication used for addiction (naltrexone) and depression/smoking cessation (bupropion).
Indicated specifically for severe obesity caused by certain rare genetic conditions affecting the MC4R pathway (e.g., POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome). Requires genetic testing to confirm eligibility.
COVERAGE & COST
INSURANCE & PRICING
Coverage for anti-obesity medications varies by plan. We help you navigate prior authorization, verify your benefits, and find the most affordable path — including manufacturer savings programs.
✓
Coverage Verification
We check your plan before prescribing and identify which medications are covered.
📋
Prior Authorization
Most GLP-1s require prior auth. We handle the paperwork and advocate on your behalf.
💊
Cash-Pay Options
Oral Wegovy and Foundayo are available starting at ~$149/month for self-pay patients.
Find the Right Medication for You
Every patient is different. Dr. Koohsari will review your health history, goals, and insurance to recommend the best treatment — injectable or oral, new or established.
